Trial Profile

A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Subjects With Acute Myeloid Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entospletinib (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin; Decitabine
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Gilead Sciences

06 Jun 2023 Results of a clinical efficacy report includes one patient from group A (newly diagnosed AML, MLL-r, 14-day monotherapy lead-in with ENTO) and two patients from group C monotherapy (relapsed/refractory AML, MLL-r) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
20 Aug 2020 Results published in the Clinical Cancer Research
15 Mar 2019 This trial has been completed in Germany (End date-2019-02-21), according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com